Atomistry » Magnesium » PDB 3fps-3fzi » 3frg
Atomistry »
  Magnesium »
    PDB 3fps-3fzi »
      3frg »

Magnesium in PDB 3frg: Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor

Enzymatic activity of Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor

All present enzymatic activity of Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor:
3.1.4.17;

Protein crystallography data

The structure of Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor, PDB code: 3frg was solved by D.O.Somers, M.Neu, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 20.00 / 1.70
Space group I 21 21 21
Cell size a, b, c (Å), α, β, γ (°) 88.485, 94.831, 105.320, 90.00, 90.00, 90.00
R / Rfree (%) 20.9 / 24.2

Other elements in 3frg:

The structure of Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor also contains other interesting chemical elements:

Arsenic (As) 4 atoms
Zinc (Zn) 1 atom

Magnesium Binding Sites:

The binding sites of Magnesium atom in the Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor (pdb code 3frg). This binding sites where shown within 5.0 Angstroms radius around Magnesium atom.
In total only one binding site of Magnesium was determined in the Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor, PDB code: 3frg:

Magnesium binding site 1 out of 1 in 3frg

Go back to Magnesium Binding Sites List in 3frg
Magnesium binding site 1 out of 1 in the Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor


Mono view


Stereo pair view

A full contact list of Magnesium with other atoms in the Mg binding site number 1 of Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with A Quinoline Inhibitor within 5.0Å range:
probe atom residue distance (Å) B Occ
A:Mg505

b:22.6
occ:1.00
 O A:HOH582 2.1 21.2 1.0
OD1 A:ASP275 2.1 17.8 1.0
O A:HOH581 2.1 21.8 1.0
O A:HOH585 2.1 18.9 1.0
O A:HOH580 2.2 19.3 1.0
O A:HOH579 2.2 20.1 1.0
CG A:ASP275 3.1 16.4 1.0
OD2 A:ASP275 3.4 16.7 1.0
ZN A:ZN504 3.8 21.8 1.0
OE2 A:GLU304 4.1 20.5 1.0
O A:HOH522 4.1 22.0 1.0
O A:HOH668 4.1 22.7 1.0
O A:HIS274 4.1 17.9 1.0
NE2 A:HIS307 4.1 16.0 1.0
CD2 A:HIS274 4.2 17.0 1.0
OG1 A:THR345 4.2 20.8 1.0
O25 A:SK41 4.3 26.0 1.0
CD2 A:HIS307 4.5 18.6 1.0
CB A:ASP275 4.5 14.8 1.0
OD2 A:ASP392 4.5 24.4 1.0
CD2 A:HIS278 4.6 15.6 1.0
O A:THR345 4.6 21.2 1.0
C26 A:SK41 4.6 22.2 1.0
NE2 A:HIS274 4.7 19.7 1.0
O A:HOH615 4.7 28.4 1.0
CB A:THR345 4.8 23.6 1.0
CD2 A:HIS234 4.8 20.2 1.0
NE2 A:HIS234 4.8 19.7 1.0
CA A:ASP275 4.8 16.7 1.0
NE2 A:HIS278 4.9 17.5 1.0
CG A:GLU304 4.9 19.8 1.0
CD A:GLU304 4.9 19.6 1.0
C A:HIS274 5.0 19.5 1.0
O A:HOH523 5.0 24.8 1.0

Reference:

C.J.Lunniss, A.W.Cooper, C.D.Eldred, M.Kranz, M.Lindvall, F.S.Lucas, M.Neu, A.G.Preston, L.E.Ranshaw, A.J.Redgrave, J.Ed Robinson, T.J.Shipley, Y.E.Solanke, D.O.Somers, J.O.Wiseman. Quinolines As A Novel Structural Class of Potent and Selective PDE4 Inhibitors: Optimisation For Oral Administration. Bioorg.Med.Chem.Lett. V. 19 1380 2009.
ISSN: ISSN 0960-894X
PubMed: 19195882
DOI: 10.1016/J.BMCL.2009.01.045
Page generated: Wed Aug 14 13:52:44 2024

Last articles

Zn in 9JPJ
Zn in 9JP7
Zn in 9JPK
Zn in 9JPL
Zn in 9GN6
Zn in 9GN7
Zn in 9GKU
Zn in 9GKW
Zn in 9GKX
Zn in 9GL0
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy